Collectively, the three studies total roughly 6,000 cancer patients.
Disclosures: Dr. Stopeck serves as a consultant to Amgen and Novartis and is on the speakers bureau for Novartis, which markets zoledronic acid.
There is no need to monitor serum creatinine in patients on denosumab, unlike with the bisphosphonate.
Source DR. STOPECK